New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
19:56 EDTHZNPHorizon presents data showing effectiveness of RAYOS
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:22 EDTHZNPHorizon Pharma granted Notice of Allowance for Pennsaid by USPTO
Subscribe for More Information
August 21, 2015
13:04 EDTHZNPDepomed to file revocation statement with SEC
Subscribe for More Information
August 20, 2015
07:03 EDTHZNPHorizon Pharma issued Notice of Allowance by USPTO covering Vimovo
Subscribe for More Information
August 19, 2015
17:40 EDTHZNPDepomed sends letter to Horizon Pharma CEO
Subscribe for More Information
17:36 EDTHZNPDepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use